RADNOR, Pa., May 18, 2021 (GLOBE NEWSWIRE) — The law firm of Kessler Topaz Meltzer & Check, LLP reminds Emergent BioSolutions Inc. (NYSE: EBS) (“Emergent”) investors that the firm has filed a securities fraud class action lawsuit in the United States District Court for the District of Maryland against Emergent on behalf of those who purchased or acquired Emergent common stock between April 24, 2020 and April 16, 2021, inclusive (the “Class Period”). This action, captioned Roth v. Emergent BioSolutions Inc., et al., Case No. 1:21-cv-01189-PX (the “Roth Action”), was filed in the United States District Court for the District of Maryland (Southern Division). To view a copy of the Roth Action complaint, please click here.
Lead Plaintiff Deadline: June 18, 2021
Emergent is a specialty biopharmaceutical company that develops vaccines and antibody therapeutics for infectious diseases.
The Roth Action alleges that, throughout the Class Period, the defendants failed to disclose that: (1) Emergent’s Baltimore facility had a history of manufacturing issues increasing the likelihood for massive contaminations; (2) the Baltimore facility had received a series of Food and Drug Administration (“FDA”) citations as a result of these contamination risks and quality control issues; (3) Emergent had been forced to discard millions of doses of COVID-19 vaccines after workers at the facility deviated from manufacturing standards; and (4) as a result of the foregoing, the defendants’ public statements about Emergent’s ability and capacity to mass manufacture multiple COVID-19 vaccines at its Baltimore facility were materially false and/or misleading and/or lacked a reasonable basis.
Emergent investors may, no later than June 18, 2021, seek to be appointed as a lead plaintiff representative of the class through Kessler Topaz Meltzer & Check, LLP or other counsel, or may choose to do nothing and remain an absent class member. A lead plaintiff is a representative party who acts on behalf of all class members in directing the litigation. In order to be appointed as a lead plaintiff, the Court must determine that the class member’s claim is typical of the claims of other class members, and that the class member will adequately represent the class. Your ability to share in any recovery is not affected by the decision of whether or not to serve as a lead plaintiff.
Kessler Topaz Meltzer & Check, LLP prosecutes class actions in state and federal courts throughout the country involving securities fraud, breaches of fiduciary duties and other violations of state and federal law. Kessler Topaz Meltzer & Check, LLP is a driving force behind corporate governance reform, and has recovered billions of dollars on behalf of institutional and individual investors from the United States and around the world. The firm represents investors, consumers and whistleblowers (private citizens who report fraudulent practices against the government and share in the recovery of government dollars). For more information about Kessler Topaz Meltzer & Check, LLP please visit www.ktmc.com.
CONTACT:
Kessler Topaz Meltzer & Check, LLP
James Maro, Jr., Esq.
Adrienne Bell, Esq.
280 King of Prussia Road
Radnor, PA 19087
(844) 887-9500 (toll free)
info@ktmc.com
The post Class Action Deadline Reminder: Kessler Topaz Meltzer & Check, LLP Reminds Emergent BioSolutions Inc. Investors of Deadline in Securities Fraud Class Action Lawsuit appeared first on CaymanMama.com | News.
from CaymanMama.com | News https://ift.tt/3bEz2tz
No comments:
Post a Comment